Clinical approach of Cardiovascular Disease in Women

Short Communication - Journal of Cardiovascular Medicine and Therapeutics (2020) Volume 4, Issue 3

The burden of cardiovascular disease in women, is a clinical challenge in several levels.

The Author trough the presentation of cases, remarks the clinical differences and a practical approach of the attention of these population.

Inflammation is an obligatory marker of arterial disease, both stemming from the inflammatory activity of cholesterol itself and from

well-established molecular mechanisms. Raised progenitor cell recruitment after major events and clonal hematopoiesis related

mechanisms have provided an improved understanding of factors regulating inflammatory phenomena. Trials with inflammation

antagonists have led to an extensive evaluation of biomarkers such as the high sensitivity C reactive protein (hsCRP), not exerting a

causative role, but frequently indicative of the individual cardiovascular (CV) risk. Aim of this review is to provide indication on the

anti-inflammatory profile of agents of general use in CV prevention, i.e. affecting lipids, blood pressure, diabetes as well nutraceuticals

such as n-3 fatty acids. A crucial issue in the evaluation of the benefit of the anti-inflammatory activity is the frequent discordance

between a beneficial activity on a major risk factor and associated changes of hsCRP, as in the case of statins vs PCSK9 antagonists.

In hypertension, angiotensin converting enzyme inhibitors exert an optimal anti-inflammatory activity, vs the case of sartans.

Author(s): Yamilah Bouzid